KMDA
Price
$7.14
Change
+$0.08 (+1.13%)
Updated
Sep 5 closing price
Capitalization
401.71M
65 days until earnings call
SCYX
Price
$0.89
Change
+$0.02 (+2.30%)
Updated
Sep 5 closing price
Capitalization
37.31M
58 days until earnings call
Interact to see
Advertisement

KMDA vs SCYX

Header iconKMDA vs SCYX Comparison
Open Charts KMDA vs SCYXBanner chart's image
Kamada
Price$7.14
Change+$0.08 (+1.13%)
Volume$129.8K
Capitalization401.71M
SCYNEXIS
Price$0.89
Change+$0.02 (+2.30%)
Volume$191.49K
Capitalization37.31M
KMDA vs SCYX Comparison Chart in %
Loading...
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KMDA vs. SCYX commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a Hold and SCYX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (KMDA: $7.14 vs. SCYX: $0.89)
Brand notoriety: KMDA and SCYX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: KMDA: 257% vs. SCYX: 109%
Market capitalization -- KMDA: $401.71M vs. SCYX: $37.31M
KMDA [@Pharmaceuticals: Generic] is valued at $401.71M. SCYX’s [@Pharmaceuticals: Generic] market capitalization is $37.31M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KMDA’s FA Score shows that 0 FA rating(s) are green whileSCYX’s FA Score has 0 green FA rating(s).

  • KMDA’s FA Score: 0 green, 5 red.
  • SCYX’s FA Score: 0 green, 5 red.
According to our system of comparison, both KMDA and SCYX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KMDA’s TA Score shows that 6 TA indicator(s) are bullish while SCYX’s TA Score has 6 bullish TA indicator(s).

  • KMDA’s TA Score: 6 bullish, 4 bearish.
  • SCYX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both KMDA and SCYX are a good buy in the short-term.

Price Growth

KMDA (@Pharmaceuticals: Generic) experienced а +3.18% price change this week, while SCYX (@Pharmaceuticals: Generic) price change was +7.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

KMDA is expected to report earnings on Nov 12, 2025.

SCYX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KMDA($402M) has a higher market cap than SCYX($37.3M). KMDA has higher P/E ratio than SCYX: KMDA (22.31) vs SCYX (0.91). KMDA YTD gains are higher at: 20.601 vs. SCYX (-26.446). KMDA has higher annual earnings (EBITDA): 34.2M vs. SCYX (-19.29M). KMDA has more cash in the bank: 66M vs. SCYX (44.8M). SCYX has less debt than KMDA: SCYX (2.39M) vs KMDA (11.4M). KMDA has higher revenues than SCYX: KMDA (170M) vs SCYX (3.26M).
KMDASCYXKMDA / SCYX
Capitalization402M37.3M1,078%
EBITDA34.2M-19.29M-177%
Gain YTD20.601-26.446-78%
P/E Ratio22.310.912,465%
Revenue170M3.26M5,220%
Total Cash66M44.8M147%
Total Debt11.4M2.39M477%
FUNDAMENTALS RATINGS
KMDA vs SCYX: Fundamental Ratings
KMDA
SCYX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7897
PRICE GROWTH RATING
1..100
5255
P/E GROWTH RATING
1..100
3798
SEASONALITY SCORE
1..100
7521

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCYX's Valuation (45) in the Pharmaceuticals Other industry is in the same range as KMDA (71) in the Biotechnology industry. This means that SCYX’s stock grew similarly to KMDA’s over the last 12 months.

SCYX's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as KMDA (100) in the Biotechnology industry. This means that SCYX’s stock grew similarly to KMDA’s over the last 12 months.

KMDA's SMR Rating (78) in the Biotechnology industry is in the same range as SCYX (97) in the Pharmaceuticals Other industry. This means that KMDA’s stock grew similarly to SCYX’s over the last 12 months.

KMDA's Price Growth Rating (52) in the Biotechnology industry is in the same range as SCYX (55) in the Pharmaceuticals Other industry. This means that KMDA’s stock grew similarly to SCYX’s over the last 12 months.

KMDA's P/E Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for SCYX (98) in the Pharmaceuticals Other industry. This means that KMDA’s stock grew somewhat faster than SCYX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KMDASCYX
RSI
ODDS (%)
Bullish Trend 4 days ago
60%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
60%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
59%
Bullish Trend 4 days ago
74%
MACD
ODDS (%)
Bullish Trend 4 days ago
67%
Bullish Trend 4 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
63%
Bullish Trend 4 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
69%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
65%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 11 days ago
66%
Bearish Trend 21 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
60%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
58%
Bullish Trend 4 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MDBH3.600.11
+3.23%
MDB Capital Holdings LLC
LRCX102.952.53
+2.52%
Lam Research Corp
MAT18.820.17
+0.91%
Mattel
GWRS9.780.07
+0.77%
Global Water Resources
WABC49.53-0.59
-1.18%
Westamerica Bancorporation

KMDA and

Correlation & Price change

A.I.dvisor tells us that KMDA and SIGA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and SIGA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
+1.13%
SIGA - KMDA
32%
Poorly correlated
-0.82%
OGI - KMDA
26%
Poorly correlated
+2.48%
RDY - KMDA
24%
Poorly correlated
+1.34%
SCYX - KMDA
23%
Poorly correlated
+2.43%
EBS - KMDA
23%
Poorly correlated
-0.66%
More

SCYX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCYX has been loosely correlated with AKAN. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SCYX jumps, then AKAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
+2.43%
AKAN - SCYX
35%
Loosely correlated
-2.54%
ELAN - SCYX
31%
Poorly correlated
+5.50%
AQST - SCYX
30%
Poorly correlated
+7.11%
SIGA - SCYX
28%
Poorly correlated
-0.82%
CRDL - SCYX
26%
Poorly correlated
-1.80%
More